托美丁所致假蛋白尿掩盖的金诺芬引起的金肾病
Gold nephropathy due to auranofin obscured by tolmetin pseudoproteinuria.
作者信息
Wilson A P, Prouse P J, Gumpel J M
出版信息
Ann Rheum Dis. 1984 Jun;43(3):511-2. doi: 10.1136/ard.43.3.511.
Abstract
A 63-year-old woman with seropositive rheumatoid arthritis was successfully treated with auranofin for 12 months. Heavy proteinuria then developed and the drug was stopped. However, the proteinuria apparently became worse. This was later recognised to be a spurious effect due to the introduction of tolmetin. Renal biopsy showed a type I membranous glomerulonephropathy.
摘要
一名63岁血清反应阳性类风湿性关节炎女性患者接受金诺芬治疗12个月，效果良好。随后出现大量蛋白尿，遂停用该药。然而，蛋白尿情况明显恶化。后来发现这是由于引入托美汀所致的假性效应。肾活检显示为I型膜性肾小球肾病。
相似文献
1
Gold nephropathy due to auranofin obscured by tolmetin pseudoproteinuria.托美丁所致假蛋白尿掩盖的金诺芬引起的金肾病
Ann Rheum Dis. 1984 Jun;43(3):511-2. doi: 10.1136/ard.43.3.511.
2
Proteinuria in gold-treated rheumatoid arthritis.金制剂治疗的类风湿关节炎中的蛋白尿
Ann Intern Med. 1984 Aug;101(2):176-9. doi: 10.7326/0003-4819-101-2-176.
3
Injectable gold dermatitis and proteinuria: retreatment with auranofin.注射用金剂所致皮炎和蛋白尿：用金诺芬再治疗
Int J Clin Pharmacol Res. 1985;5(4):265-8.
4
Proteinuria and oral gold treatment.蛋白尿与口服金制剂治疗
Ann Intern Med. 1985 Apr;102(4):561-2. doi: 10.7326/0003-4819-102-4-561.
5
Membranous glomerulonephritis as a complication of oral gold therapy.膜性肾小球肾炎作为口服金制剂治疗的一种并发症。
Ann Intern Med. 1982 Oct;97(4):563-4. doi: 10.7326/0003-4819-97-4-563.
6
Failure of sodium aurothiomalate and triethyl phosphine gold to cause renal tubular injury in rheumatoid arthritis: implications for the aetiology of gold-related nephropathy.硫代苹果酸金钠和三乙膦金未能在类风湿关节炎中导致肾小管损伤：对金相关性肾病病因学的启示。
Clin Rheumatol. 1983 Sep;2(3):273-6. doi: 10.1007/BF02041402.
7
Auranofin (SK + F 39162) induced enterocolitis in rheumatoid arthritis. A case report.金诺芬（SK + F 39162）诱发类风湿关节炎患者发生小肠结肠炎。病例报告。
Scand J Rheumatol. 1983;12(3):254-6. doi: 10.3109/03009748309098544.
8
[Preliminary results of oral gold treatment with auranofin following lack of success of intramuscular gold therapy].
Wien Klin Wochenschr Suppl. 1984;156:49-51.
9
Auranofin: experience to date.金诺芬：迄今为止的经验。
Am J Med. 1983 Dec 30;75(6A):86-9. doi: 10.1016/0002-9343(83)90480-1.
10
A 12-month comparative trial of auranofin and D-penicillamine in rheumatoid arthritis.金诺芬与青霉胺治疗类风湿关节炎的12个月对比试验。
Am J Med. 1983 Dec 30;75(6A):138-41. doi: 10.1016/0002-9343(83)90487-4.
本文引用的文献
1
Membranous glomerulonephritis as a complication of oral gold therapy.膜性肾小球肾炎作为口服金制剂治疗的一种并发症。
Ann Intern Med. 1982 Oct;97(4):563-4. doi: 10.7326/0003-4819-97-4-563.
2
HLA-DR antigens and toxic reaction to sodium aurothiomalate and D-penicillamine in patients with rheumatoid arthritis.类风湿关节炎患者的HLA - DR抗原与金硫代苹果酸钠和青霉胺的毒性反应
N Engl J Med. 1980 Aug 7;303(6):300-2. doi: 10.1056/NEJM198008073030602.
3
Pseudoproteinuria in tolmetin-treated patients.服用托美汀患者的假性蛋白尿
Clin Pharmacol Ther. 1975 Apr;17(4):467-8. doi: 10.1002/cpt1975174467.
4
Reversible proteinuria as a complication of oral gold therapy.可逆性蛋白尿作为口服金制剂治疗的一种并发症。
Arthritis Rheum. 1979 Dec;22(12):1417-8. doi: 10.1002/art.1780221223.
Zotero 插件